An α2-AR antagonist and active metabolite of azapirones
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

2-(1-Piperazinyl)pyrimidine

Item No. 34091

Technical Information
CAS Number
20980-22-7
Synonyms
  • PmP
  • 1-PP
  • 1-(2-Pyrimidyl)piperazine
Molecular Formula
C8H12N4
Formula Weight
Purity
≥98%
A solid
DMF: 10 mg/mlDMSO: 10 mg/mlEthanol: 10 mg/mlPBS (pH 7.2): 10 mg/ml
λmax
247 nm
SMILES
C1(N2CCNCC2)=NC=CC=N1
InChi Code
InChI=1S/C8H12N4/c1-2-10-8(11-3-1)12-6-4-9-5-7-12/h1-3,9H,4-7H2
InChi Key
MRBFGEHILMYPTF-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    2-(1-Piperazinyl)pyrimidine is an antagonist of α2-adrenergic receptors (α2-ARs; pA2 = 6.8 in rat brain synaptosomes) and an active metabolite of various azapirones.1,2,3,4 It is an active metabolite of tandospirone (Item No. 40436), buspirone, ipsapirone (Item No. 39918 | 22075), and gepirone, among others. 2-(1-Piperazinyl)pyrimidine prevents clonidine-induced slowing of gastrointestinal transit in rats (ED50 = 0.8 mg/kg).2 It increases drinking in the Vogel punished drinking task, indicating anxiolytic-like activity, in rats when administered at doses ranging from 1 to 4 mg/kg.3 2-(1-Piperazinyl)pyrimidine (0.25-1 mg/kg) also reduces the amplitude of electrically stimulated excitatory post-synaptic potentials (EPSPs) in the hippocampal CA1 region in rats, an effect that can be blocked by the serotonin (5-HT) receptor subtype 5-HT1A antagonist spiroxatrine.4 It has also been used as a phosphopeptide derivatization agent.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Gobbi, M., Frittoli, E., and Mennini, T. Antagonist properties of 1-(2-pyrimidinyl)piperazine at presynaptic α2-adrenoceptors in the rat brain. Eur. J. Pharmacol. 180(1), 183-186 (1990).

    2. Bianchi, G., Caccia, S., Della Vedova, F., et alThe α2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). Eur. J. Pharmacol. 151(3), 365-371 (1988).

    3. Gower, A.J., and Tricklebank, M.D. α2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat. Eur. J. Pharmacol. 155(1-2), 129-137 (1988).

    4. Manahan-Vaughan, D., Anwyl, R., and Rowan, M.J. The azapirone metabolite 1-(2-pyrimidinyl)piperazine depresses excitatory synaptic transmission in the hippocampus of the alert rat via 5-HT1A receptors. Eur. J. Pharmacol. 294(2-3), 617-624 (1995).

    5. Zhang, L., Xu, Y., Lu, H., et alCarboxy group derivatization for enhanced electron-transfer dissociation mass spectrometric analysis of phosphopeptides. Proteomics 9(16), 4093-4097 (2009).